Abstract
Ribozymes are involved in strategies to block gene expression and have been used as agents against viral infections and cancer. Emphasis has been on studies using hairpin and hammerhead ribozymes. The uniqueness of ribozymes is that they posses multiple turnover allowing high efficiency as antiviral agents. Ribozymes have been directed to human immunodeficiency virus (HIV), hepatitis (B, C and E) and human papillomavirus (HPV), the cause of cervical cancer. The mode of action of antiviral ribozymes, their structure and their in vitro effectiveness as inhibitors of HIV, HBV, HCV, HEV and HPV is reviewed. Although ribozymes have been demonstrated as effective antivirals in cell culture and some animal models, clinical studies have been limited. Nevertheless, ribozymes remain as a viable alternative to antisense and RNA interference
Keywords: Ribozyme, catalytic RNA, antisense, ribonucleic acid, RNA, papillomavirus, AIDS, hepatitis virus, hepadnavirus, HIV, HPV
Letters in Drug Design & Discovery
Title: Utilization of Ribozymes as Antiviral Agents
Volume: 3 Issue: 6
Author(s): M. L. Benitez-Hess and L. M. Alvarez-Salas
Affiliation:
Keywords: Ribozyme, catalytic RNA, antisense, ribonucleic acid, RNA, papillomavirus, AIDS, hepatitis virus, hepadnavirus, HIV, HPV
Abstract: Ribozymes are involved in strategies to block gene expression and have been used as agents against viral infections and cancer. Emphasis has been on studies using hairpin and hammerhead ribozymes. The uniqueness of ribozymes is that they posses multiple turnover allowing high efficiency as antiviral agents. Ribozymes have been directed to human immunodeficiency virus (HIV), hepatitis (B, C and E) and human papillomavirus (HPV), the cause of cervical cancer. The mode of action of antiviral ribozymes, their structure and their in vitro effectiveness as inhibitors of HIV, HBV, HCV, HEV and HPV is reviewed. Although ribozymes have been demonstrated as effective antivirals in cell culture and some animal models, clinical studies have been limited. Nevertheless, ribozymes remain as a viable alternative to antisense and RNA interference
Export Options
About this article
Cite this article as:
Benitez-Hess L. M. and Alvarez-Salas M. L., Utilization of Ribozymes as Antiviral Agents, Letters in Drug Design & Discovery 2006; 3 (6) . https://dx.doi.org/10.2174/157018006777805521
DOI https://dx.doi.org/10.2174/157018006777805521 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism Antioxidant Effects and in vitro Cytotoxicity on Human Cancer Cell Lines of Flavonoid-Rich Flamboyant (<i>Delonix regia</i> (Bojer) Raf.) Flower Extract
Current Pharmaceutical Biotechnology Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Selenium Nanoparticles in Folate-Targeted Delivery of the pCMV-Luc DNA Reporter Gene
Current Nanoscience Development of Global Consensus of Dengue Virus Envelope Glycoprotein for Epitopes Based Vaccine Design
Current Computer-Aided Drug Design The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets